Andrew Zappia, a partner in Troutman Pepper Locke's Health Care + Life Sciences Intellectual Property group

24 November 2025FeaturesAmericasAndrew Zappia

Still Unsettling: The uncertain landscape for discretionary denial

The USPTO’s ‘settled expectations’ rule is anything but settled, argues Andrew Zappia of Troutman Pepper Locke.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Americas

Settled expectations, the six-year rule, and developments in USPTO policy

6 November 2026 Uncertainty over whether a patent can be challenged through inter partes review at the USPTO has only increased since the discretionary denial policy was introduced, so how should companies plan? Mauricio Uribe and Maria Anderson of Davis Wright Tremaine explain.

Americas

Court upholds $83m sequencing verdict and sets royalty rate

17 June 2026 A cancer diagnostics company has lost its bid to overturn a jury verdict in a major patent dispute that has also spawned parallel proceedings before the Federal Circuit and PTAB.

Americas

Amgen and subsidiary dealt $20m blow over rodent antibody tech

15 June 2026 Unanimous jury finds willful infringement, with the possibility of a trebled award and a much larger feud still to come.